BioMS Medical Plunges as Much as 56% After Test Misses Target Bloomberg - 30 (Bloomberg) -- BioMS Medical Corp., a biotechnology company in Edmonton, Alberta, plunged as much as 56 percent after its multiple-sclerosis treatment ... BioMS multiple sclerosis drug fails mid-stage study BioMS Medical reports results of exploratory phase II trial of ... BioMS says mid-stage trial of Dirucotide in relapsing- remitting ... |
BioMS Medical Plunges as Much as 56% After Test Misses Target - Bloomberg
[link]
[powered by WordPress.]
